Literature DB >> 29084204

Recommendations for reporting post-transplant relapse in AML.

A Rashidi1, M A Linden2, M-E Percival3, B M Sandmaier3, S Devine4, D J Weisdorf1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 29084204     DOI： 10.1038/bmt.2017.227

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  21 in total

1.  Using Minimal Residual Disease to Improve Treatment Response Definitions and Hematopoietic Cell Transplantation Strategy in Acute Leukemia.

Authors:  Renato Bassan
Journal:  J Clin Oncol       Date:  2015-12-14       Impact factor: 44.544

2.  Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.

Authors:  Mi Kwon; Carolina Martínez-Laperche; María Infante; Fernando Carretero; Pascual Balsalobre; David Serrano; Jorge Gayoso; Ana Pérez-Corral; Javier Anguita; Jose Luis Díez-Martín; Ismael Buño
Journal:  Biol Blood Marrow Transplant       Date:  2012-01-25       Impact factor: 5.742

3.  Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse.

Authors:  O Horky; J Mayer; L Kablaskova; F Razga; M Krejci; J Kissova; M Borsky; I Jeziskova; D Dvorakova
Journal:  Int J Lab Hematol       Date:  2011-02       Impact factor: 2.877

4.  Non-leukemic autologous reconstitution after allogeneic bone marrow transplantation for Ph-positive chronic myelogenous leukemia: extended remission preceding eventual relapse.

Authors:  C G Brunstein; B A Hirsch; J S Miller; R C McGlennen; C M Verfaillie; P B McGlave; D J Weisdorf
Journal:  Bone Marrow Transplant       Date:  2000-12       Impact factor: 5.483

5.  Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study.

Authors:  Nelli Bejanyan; Daniel J Weisdorf; Brent R Logan; Hai-Lin Wang; Steven M Devine; Marcos de Lima; Donald W Bunjes; Mei-Jie Zhang
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-15       Impact factor: 5.742

6.  Isolated Extramedullary Relapse of Acute Leukemia after Allogeneic Stem Cell Transplantation: Different Kinetics and Better Prognosis than Systemic Relapse.

Authors:  Noga Shem-Tov; Francesco Saraceni; Ivetta Danylesko; Roni Shouval; Ronit Yerushalmi; Arnon Nagler; Avichai Shimoni
Journal:  Biol Blood Marrow Transplant       Date:  2017-04-07       Impact factor: 5.742

7.  Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms' tumor 1 expression.

Authors:  Giovanni Rossi; Angelo Michele Carella; Maria Marta Minervini; Francesco di Nardo; Chiara de Waure; Michele Mario Greco; Emanuela Merla; Giovanni Pio de Cillis; Nicola Di Renzo; Angela Melpignano; Silvana Capalbo; Gaetano Palumbo; Giovanni Pisapia; Nicola Cascavilla
Journal:  Leuk Res       Date:  2014-11-29       Impact factor: 3.156

Review 8.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

9.  Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.

Authors:  U Platzbecker; M Wermke; J Radke; U Oelschlaegel; F Seltmann; A Kiani; I-M Klut; H Knoth; C Röllig; J Schetelig; B Mohr; X Graehlert; G Ehninger; M Bornhäuser; C Thiede
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

10.  Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.

Authors:  Y Zhou; M Othus; D Araki; B L Wood; J P Radich; A B Halpern; M Mielcarek; E H Estey; F R Appelbaum; R B Walter
Journal:  Leukemia       Date:  2016-02-29       Impact factor: 11.528
View more
  2 in total

1.  [Prognostic value of donor chimerism at +90 days after allogeneic hematopoietic stem cell transplantation in young patients with intermediate-risk acute myeloid leukemia].

Authors:  Y Fei; X X Hu; Q Chen; A J Huang; H Cheng; X Ni; H Y Qiu; L Gao; G S Tang; J Chen; W P Zhang; J M Yang; J M Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-12-14

2.  Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation.

Authors:  Elizabeth A de Kort; Heleen S de Lil; Manita E J Bremmers; Lenneke F J van Groningen; Nicole M A Blijlevens; Gerwin Huls; Roger J M Brüggemann; Suzanne van Dorp; Walter J F M van der Velden
Journal:  PLoS One       Date:  2019-03-21       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.